SRIN Therapeutics Inc.

SRIN Therapeutics Inc. is a Philadelphia-based pharmaceutical company founded in 2018 that focuses on developing novel treatments by harnessing the endocannabinoid system. The company is engaged in pharmaceutical manufacturing and research, specifically working on cannabinoid-based drug candidates intended to address various medical conditions, including cancer, autism, and post-traumatic stress disorder. Their therapeutic approach aims to mitigate the side effects of chemotherapy and provide cost-effective treatment alternatives. The company has pursued intellectual property protection for its developments, including patent applications related to cannabinoid compositions for immune modulation.

The company's mission is to fulfill unmet medical needs for patients globally by leveraging innovative therapeutic solutions. By focusing on the endocannabinoid system, SRIN Therapeutics seeks to offer safer or more accessible alternatives to traditional treatments such as opioid-based pain medications. The organization is led by founder and CEO Akhil Alugupalli and operates with a small, specialized team. The company remains in the development and research phase, with activities that have included the initiation of clinical trials and the pursuit of regulatory pathways for its pipeline drugs.